Pred Forte

(Prednisolone acetate)

ApprovedSmall molecule

Prednisolone acetate is a steroid eye drop used to reduce inflammation and swelling in the eyes, often after surgery or for inflammatory eye conditions like uveitis.[2] Pred Forte is currently approved and in use across 22 indications[4].[1]

Pred Forte is one of 374 small molecule programs targeting Low back pain. It is currently in Approved.

Indications

Total Trials

Active Trials

373

Competitors

Pipeline

Status by Indication[4][1]

Indication

Low Back PainActive, not recruiting

Corneal ScarringUnknown

Allergic ConjunctivitisUnknown

IritisActive, not recruiting

Anterior UveitisActive, not recruiting

GlaucomaActive, not recruiting

KeratoconusActive, not recruiting

Epiretinal MembraneActive, not recruiting

Retinal DetachmentActive, not recruiting

Macular Retinal EdemaActive, not recruiting

Low Back PainPhase 3

Active, not recruiting

Corneal ScarringPreclinical

Unknown

Allergic ConjunctivitisPreclinical

Unknown

IritisPreclinical

Active, not recruiting

Anterior UveitisPhase 3

Active, not recruiting

GlaucomaPhase 2

Active, not recruiting

KeratoconusPhase 1

Active, not recruiting

Epiretinal MembranePreclinical

Active, not recruiting

Retinal DetachmentApproved

Active, not recruiting

Macular Retinal EdemaPhase 2

Active, not recruiting

Showing 10 of 22 indications

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Pred Forte

Novartis

Approved

1 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 9

Prednisone/prednisolone

Roche

Preclinical

3 10

Ifex

BBaxter Healthcare Corporation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

N/ARecruiting

Refractory

NCT03415828

Clinical

Trials by Indication[1]

Cataract6 trials

A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery

Completed· Novartis logo

Novartis·Phase 4·NCT00170729·62 enrolled

Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery

Completed·BBp Consulting, Inc·Phase 4·NCT00758199·49 enrolled

KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children

Terminated·KKala Pharmaceuticals, Inc.·Phase 3·NCT03596723·2 enrolled

Show 3 more trials

In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery

Completed·VVance Thompson Vision·Phase 4·NCT05023304·30 enrolled

Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

Recruiting·EEyePoint Pharmaceuticals, Inc.·Phase 4·NCT05191706·60 enrolled

Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population

Recruiting·SSalvat·Phase 3·NCT05724446·60 enrolled

Prednisolone3 trials

A Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers

Completed· Novartis logo

Novartis·Phase 4·NCT00134992·30 enrolled

A Comparison of Three Different Formulations of Prednisolone Acetate 1%

Completed·IIndiana University School of Medicine·Phase 4·NCT00345046·60 enrolled

A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%

Completed·RResearch Insight LLC·Phase 4·NCT04273282·31 enrolled

Anterior Uveitis2 trials

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

Completed·VVivaVision Biotech, Inc·Phase 2·NCT06679153·89 enrolled

A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis

Completed·AAldeyra Therapeutics, Inc.·Phase 2·NCT02406209·45 enrolled

Macular Edema2 trials

Nepafenac Once Daily for Macular Edema - Study 1

Completed·AAlcon Research·Phase 3·NCT01853072·881 enrolled

Nepafenac Once Daily for Macular Edema - Study 2

Completed·AAlcon Research·Phase 3·NCT01872611·819 enrolled

Uveitis2 trials

Study of Difluprednate in the Treatment of Uveitis

Completed·SSirion Therapeutics, Inc.·Phase 3·NCT00501579

Macular Edema Nepafenac vs. Difluprednate Uveitis Trial

Terminated·UUniversity of California, San Francisco·Phase 4·NCT01939691·9 enrolled

17 more indications

Retinal Vein Occlusion1 trial

To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions

Completed·PPalo Alto Medical Foundation·Phase 2/3·NCT00493064·63 enrolled

Retinal Detachment1 trial

Assessing the Efficacy and Safety of DEXTENZA in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment

Terminated·MMidwest Eye Institute·Phase 4·NCT04464629·7 enrolled

Inflammation1 trial

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

Terminated·RRetina Vitreous Associates of Florida·Phase 4·NCT04563299·10 enrolled

Prostate Cancer1 trial

The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT05461261·50 enrolled

Recovery1 trial

Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing FLACS With Premium IOL

Unknown status·SSight Medical Doctors PLLC·Phase 4·NCT04863742·30 enrolled

Epiretinal membrane1 trial

Topical Use of Corticosteroid to Prevent Epiretinal Membrane Following Retinal Tear

Completed·UUnity Health Toronto·N/A·NCT02412059·200 enrolled

Rejection1 trial

Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)

Completed·PPrice Vision Group·Phase 2·NCT01448213·264 enrolled

Pneumonia1 trial

Research on the Treatment of Severe Community-acquired Pneumonia in Children

Unknown status·BBaoping XU·Phase 4·NCT05768204·160 enrolled

ESS1 trial

Assessing Dextenza Insert After SMILE Procedure

Completed·WWilliam Wiley, MD·Phase 4·NCT04380857·20 enrolled

Diabetic Retinopathy1 trial

A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients

Completed·AAlcon Research·Phase 2·NCT00782717·263 enrolled

Non-Infectious Anterior Uveitis1 trial

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis

Completed·EEyegate Pharmaceuticals, Inc.·Phase 3·NCT02517619·251 enrolled

Pterygium1 trial

Dextenza for Post-operative Treatment of Pterygium

Completed·BBrandon Eye Associates, PA·Phase 4·NCT04351737·20 enrolled

Refractory1 trial

Ethanol Gel Versus Steroid in Refractory Lumbar Discogenic Pain

Recruiting·GGelscom SAS·N/A·NCT03415828·230 enrolled

Ketorolac1 trial

Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation

Completed·IInnovative Medical·Phase 4·NCT00433225

Sciatica1 trial

Efficacy of corticoïd Infiltration Via Sacro-coccygien Hiatus in Discal Sciatica

Terminated·NNantes University Hospital·Phase 3·NCT01482897·13 enrolled

Dexamethasone1 trial

Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study

Completed·SSight Medical Doctors PLLC·Phase 4·NCT04168112·20 enrolled

Unspecified1 trial

Use of Topical Euphrasia, a Homeopathic Remedy in Ophthalmology

Withdrawn·LLarkin Community Hospital·N/A·NCT02416128

Sources

References

[1]
ClinicalTrials.gov — 32 trial records for Prednisolone acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Pred Forte drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Prednisolone acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Prednisolone acetate. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Glucocorticoid Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Novartis

Pred Forte

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Cataract6 trials

Prednisolone3 trials

Anterior Uveitis2 trials

Macular Edema2 trials

Uveitis2 trials

Retinal Vein Occlusion1 trial

Retinal Detachment1 trial

Inflammation1 trial

Prostate Cancer1 trial

Recovery1 trial

Epiretinal membrane1 trial

Rejection1 trial

Pneumonia1 trial

ESS1 trial

Diabetic Retinopathy1 trial

Non-Infectious Anterior Uveitis1 trial

Pterygium1 trial

Refractory1 trial

Ketorolac1 trial

Sciatica1 trial

Dexamethasone1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News